Supernus Pharma (SUPN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4
March 12, 2015 7:21 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $16.00 (from $14.00) following Q4 results, noting continued strength for the epilepsy franchise.
Amsellem commented, "Supernus reported non-GAAP EPS of $0.08 on revenues of $31M, well... More
